AbbVie (ABBV) Stock Forecast & Price Target
ABBV Analyst Ratings
Strong Buy
20Buy4Hold0Sell
Based on 24 analysts giving stock ratings to AbbVie in the past 3 months
ABBV Stock 12 Month Forecast
Average Price Target
MXN 5,474.97▼(-1.26% Downside)Based on 24 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is MXN 5,474.97 with a high forecast of MXN 6,136.71 and a low forecast of MXN 4,342.90. The average price target represents a -1.26% change from the last price of MXN 5,545.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 6.14K
AverageMXN 5.47K
LowMXN 4.34K
Highest Price TargetHighestMXN 6,136.71Average Price TargetMXN 5,474.97Lowest Price TargetLowestMXN 4,342.90
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Asad Haider | Goldman Sachs | MXN 5,551.36 | hold | 0.11%Upside | Reiterated | 10/30/26 | ||
| David Risinger | Leerink Partners | MXN 5,268.13 | buy | -4.99%Downside | Reiterated | 10/29/26 | ||
| Louise Chen | Scotiabank | MXN 6,042.30 | buy | 8.97%Upside | Reiterated | 10/29/26 | ||
| David Amsellem | Piper Sandler | MXN 5,721.30 | buy | 3.18%Upside | Reiterated | 10/26/26 | ||
| Courtney Breen | Bernstein | MXN 4,342.90 | hold | -21.68%Downside | Reiterated | 10/25/26 | ||
| Gary Nachman | Canaccord Genuity | MXN 5,475.83 | buy | -1.25%Downside | Reiterated | 10/23/26 | ||
| Trung Huynh | RBC Capital | MXN 5,287.01 | buy | -4.65%Downside | Reiterated | 10/22/26 | ||
| Michael Yee | UBS | MXN 5,192.60 | hold | -6.36%Downside | Reiterated | 10/22/26 | ||
| Jason Gerberry | Bank of America Securities | MXN 5,759.06 | buy | 3.86%Upside | Reiterated | 10/22/26 | ||
| Terence Flynn | Morgan Stanley | MXN 5,853.47 | buy | 5.56%Upside | Reiterated | 10/22/26 | ||
| Emily Field | Barclays | MXN 5,664.65→MXN 6,136.71 | buy | 10.67%Upside | Reiterated | 10/21/26 | ||
| Geoff Meacham | Citi | MXN 4,909.37 | hold | -11.46%Downside | Reiterated | 10/20/26 | ||
| Mohit Bansal | Wells Fargo | MXN 5,664.65 | buy | 2.16%Upside | Reiterated | 10/15/26 | ||
| Evan Seigerman | BMO Capital | MXN 5,664.65 | buy | 2.16%Upside | Reiterated | 10/12/26 | ||
| Carter Gould | Cantor Fitzgerald | MXN 5,381.42→MXN 5,475.83 | buy | -1.25%Downside | Assigned | 10/08/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Asad Haider | 10/30/26 | MXN 5,551.36 | hold | 0.11%Upside | Reiterated | Goldman Sachs | ||
| David Risinger | 10/29/26 | MXN 5,268.13 | buy | -4.99%Downside | Reiterated | Leerink Partners | ||
| Louise Chen | 10/29/26 | MXN 6,042.30 | buy | 8.97%Upside | Reiterated | Scotiabank | ||
| David Amsellem | 10/26/26 | MXN 5,721.30 | buy | 3.18%Upside | Reiterated | Piper Sandler | ||
| Courtney Breen | 10/25/26 | MXN 4,342.90 | hold | -21.68%Downside | Reiterated | Bernstein | ||
| Gary Nachman | 10/23/26 | MXN 5,475.83 | buy | -1.25%Downside | Reiterated | Canaccord Genuity | ||
| Trung Huynh | 10/22/26 | MXN 5,287.01 | buy | -4.65%Downside | Reiterated | RBC Capital | ||
| Michael Yee | 10/22/26 | MXN 5,192.60 | hold | -6.36%Downside | Reiterated | UBS | ||
| Jason Gerberry | 10/22/26 | MXN 5,759.06 | buy | 3.86%Upside | Reiterated | Bank of America Securities | ||
| Terence Flynn | 10/22/26 | MXN 5,853.47 | buy | 5.56%Upside | Reiterated | Morgan Stanley | ||
| Emily Field | 10/21/26 | MXN 5,664.65→MXN 6,136.71 | buy | 10.67%Upside | Reiterated | Barclays | ||
| Geoff Meacham | 10/20/26 | MXN 4,909.37 | hold | -11.46%Downside | Reiterated | Citi | ||
| Mohit Bansal | 10/15/26 | MXN 5,664.65 | buy | 2.16%Upside | Reiterated | Wells Fargo | ||
| Evan Seigerman | 10/12/26 | MXN 5,664.65 | buy | 2.16%Upside | Reiterated | BMO Capital | ||
| Carter Gould | 10/08/26 | MXN 5,381.42→MXN 5,475.83 | buy | -1.25%Downside | Assigned | Cantor Fitzgerald |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering AbbVie
3 Months
Success Rate14/18 ratings generated profit
78%
Average Return
+9.32%
Copying Carter Gould's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +9.32% per trade.
1 Year
Success Rate26/26 ratings generated profit
100%
Average Return
+25.35%
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.35% per trade.
2 Years
Success Rate18/18 ratings generated profit
100%
Average Return
+45.86%
Copying Carter Gould's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +45.86% per trade.
ABBV Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 53 | 48 | 51 | 50 | 57 |
| Hold | 11 | 10 | 9 | 6 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 64 | 58 | 60 | 56 | 66 |
In the current month, ABBV has received 57 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 5,474.97.
ABBV Financial Forecast
HighMXN 78.53
ConsensusMXN 73.49
LowMXN 72.33
ABBV Earnings Forecast
Next quarter’s earnings estimate for ABBV is MXN 73.49 with a range of MXN 72.33 to MXN 78.53. The previous quarter’s EPS was MXN 71.77. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 348B
ConsensusMXN 343B
LowMXN 328B
ABBV Sales Forecast
Next quarter’s sales forecast for ABBV is MXN 343.50B with a range of MXN 328.15B to MXN 347.81B. The previous quarter’s sales results were MXN 326.96B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ABBV Stock Forecast FAQ
What is MX:ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is Mex$5,474.97.
What is MX:ABBV’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MX:ABBV, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AbbVie a Buy, Sell or Hold?
AbbVie has a consensus rating of Strong Buy, which is based on 20 buy ratings, 4 hold ratings and 0 sell ratings.
What is AbbVie’s share price target?
The average share price target for AbbVie is Mex$5,474.97. This is based on 24 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$6,136.71, and the lowest forecast is Mex$4,342.90. The average share price target represents a 1.26% decrease from the current price of Mex$5,545.
What do analysts say about AbbVie?
AbbVie’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Street analysts.
How can I buy shares of AbbVie?
To buy shares of MX:ABBV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.